Company news

Vera Therapeutics, Inc. news in 2024

Vera Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer

November 17, 2024

Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study

November 10, 2024

Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

November 6, 2024

Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

October 25, 2024

Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024

October 1, 2024

Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases

October 1, 2024

Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024

September 15, 2024

Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN

September 11, 2024

Vera Therapeutics to Participate at September Investor Conferences

August 28, 2024

Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

August 7, 2024

Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer

June 30, 2024

Vera Therapeutics Appoints Christy J. Oliger to Board of Directors

June 10, 2024

Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

June 6, 2024

Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)

May 27, 2024

Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress

May 24, 2024

Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

May 8, 2024

Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress

April 1, 2024

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

March 19, 2024

Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference

February 27, 2024

Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

February 1, 2024

Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock

January 31, 2024

Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock

January 28, 2024

Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy

January 24, 2024

Vera Therapeutics to Host In-Person R&D Day in New York to Present Week 72 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN on January 25, 2024

January 7, 2024

Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer

January 7, 2024

Decks in 2024